Search | Clinical Trials Finder

Conditions: Retinopathy of Prematurity (ROP)
Interventions: rhIGF-I/rhIGFBP-3; Drug
Lead sponsor: Shire; Industry
Eligibility: Up to 1 Day
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Mobile, Alabama • Irvine, California • Augusta, Georgia + 5 more

Conditions: Preeclampsia
Interventions: Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections; Other
Lead sponsor: Indiana University; Other
Eligibility: 26 Weeks and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Lung Diseases, Bronchopulmonary Dysplasia
Interventions: iNO, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 1 Year
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 14
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 11 more

Conditions: Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions: Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo; Procedure · Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 5 Minutes to 10 Days
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: Bronchopulmonary Dysplasia
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 1 Year
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bronchopulmonary Dysplasia, Neurally Adjusted Ventilatory Assist, Mechanical Ventilation
Interventions: NAVA, CMV; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 24 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Providence, Rhode Island

Conditions: Bronchopulmonary Dysplasia, Chronic Lung Disease of Newborn, Environmental Exposure
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bronchopulmonary Dysplasia
Interventions: Infasurf surfactant (ONY, Inc.), Sham (No Treatment); Drug
Lead sponsor: Roberta Ballard; Other
Eligibility: 7 Days to 14 Days
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 21
States / cities: Little Rock, Arkansas • Berkeley, California • Oakland, California + 15 more

Conditions: Anemia of Prematurity
Interventions: Red blood cell transfusion; Procedure
Lead sponsor: McMaster University; Other
Eligibility: Up to 48 Hours
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Albany, New York • Brooklyn, New York

Conditions: BPD - Bronchopulmonary Dysplasia
Interventions: NAVA technology to synchronize NIPPV; Device
Lead sponsor: New York Medical College; Other
Eligibility: 24 Weeks to 30 Weeks
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Bronchopulmonary Dysplasia (BPD), Preterm Birth Complication, Pulmonary, CPAP
Interventions: Nasal CPAP interface: OptiPAP Junior, Nasal CPAP interface: FlexiTrunk; Device
Lead sponsor: Sharp HealthCare; Other
Eligibility: Up to 30 Weeks
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Preterm Infants, Respiratory Distress Syndrome (Neonatal), BPD - Bronchopulmonary Dysplasia
Interventions: Pressure Targeted High Flow, CPAP; Procedure
Lead sponsor: University of Texas at Austin; Other
Eligibility: 7 Days to 40 Weeks
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: San Diego, California • Austin, Texas

Conditions: Bronchopulmonary Dysplasia, Hyponatremia on Diuretics
Interventions: Sodium supplementation, Fluid restriction; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 4 Weeks to 6 Months
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Chronic Lung Disease
Interventions: LOWER oxygen saturation target group, HIGHER oxygen saturation target group; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 34 Weeks to 44 Weeks
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions: recombinant human CC10 (rhCC10), placebo; Drug
Lead sponsor: Clarassance, Inc.; Industry
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 4
States / cities: Wilmington, Delaware • Baltimore, Maryland • Mineola, New York

Conditions: Bronchopulmonary Dysplasia, Prematurity
Interventions: Care coordination by telephone contacts with a nurse; Procedure
Lead sponsor: Wake Forest University; Other
Eligibility: 1 Day to 483 Days
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bronchopulmonary Dysplasia (BPD)
Interventions: Budesonide in Calfactant; Drug
Lead sponsor: Cynthia McEvoy; Other
Eligibility: 3 Days to 14 Days
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Orlando, Florida + 2 more

Conditions: Bronchopulmonary Dysplasia
Interventions: UNEX-42, Phosphate-buffered saline; Biological
Lead sponsor: United Therapeutics; Industry
Eligibility: 3 Days to 14 Days
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 1 more

Conditions: Bronchopulmonary Dysplasia
Interventions: Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose, Tobramycin solution for inhalation 300mg dose; Drug
Lead sponsor: Erik Allen Jensen; Other
Eligibility: 4 Weeks and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia, Respiration, Artificial, Respiratory Distress Syndrome, Newborn, Sepsis
Interventions: Vitamin A, Sham Procedure; Drug · Other
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 24 Hours to 96 Hours
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1999
U.S. locations: 11
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Bronchopulmonary Dysplasia (BPD), Premature Births, Critical Illness
Interventions: montelukast 4 mg granule, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 7 Days to 28 Days
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Little Rock, Arkansas • Amherst, Massachusetts • Las Vegas, Nevada + 2 more

Conditions: Bronchopulmonary Dysplasia
Interventions: Inhaled Nitric Oxide (iNO), Nitrogen (placebo); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 3 more

Conditions: Enterocolitis, Necrotizing, Bacteremia, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia, Chronic Lung Disease, Ileal Perforation
Interventions: Antibiotic, Gastric fluid, Breast milk, Stool samples, Antibiotics; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 23 Weeks to 33 Weeks
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development

Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease

NAVA vs. CMV Crossover in Severe BPD

Indoor Air Quality and Respiratory Morbidity in School-Aged Children With BPD

Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

Premature Infants in Need of Transfusion (PINT)

Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants

Parent Perceptions of OptiPAP Junior

Pressure Targeting During High Flow Therapy in Premature Infants

Management of Hyponatremia in Preterm Infants on Diuretics

BPD Saturation TARgeting

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

Post-hospitalization Nursing Effectiveness (PHONE) Study

Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Inhaled Tobramycin in BPD

Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia

Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns

Antibiotic "Dysbiosis" in Preterm Infants